Organization (Other)
IRCCS SYNLAB SDN
ClinicalTrials.gov lists IRCCS SYNLAB SDN as lead sponsor of 13 trials. It has 3 active development programs.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs. 1 trial is registered to start in 2027 or later.
This page covers IRCCS SYNLAB SDN: 13 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (15)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 |
| Alzheimer Disease | 1 |
| Atherosclerosis | 1 |
| Cardiomyopathies | 1 |
| Cardiomyopathy, Dilated | 1 |
Showing 5 of 15 disease areas.
Trials by start year as sponsor or collaborator (7)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 5 |
| 2021 | 1 |
| 2020 | 3 |
| 2019 | 1 |
| 2018 | 1 |
Recruitment duration, a model prediction: none of the 13 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (3)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Magnetic Resonance Imaging with Contrast | Alzheimer Disease | Not reported | 1 |
| Magnetic Resonance Imaging with Contrast | Dementia | Not reported | 1 |
| Observational Study | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Not reported | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 0 of 1 hit target (n=1) | not enough data |
Journals published in (40)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of the American College of Cardiology | 5 |
| European radiology | 3 |
| Alzheimer's & dementia : the journal of the Alzheimer's Association | 2 |
| Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference | 2 |
| Insights into imaging | 2 |
Showing 5 of 40 journals.
Organization relationships (3)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University Federico II of Naples, Department of Clinical and Surgical Medicine | Co sponsors trial with | 1 |
| Santobono-Pausilipon Hospital | Co sponsors trial with | 1 |
| Fondazione Santobono Pausilipon | Co sponsors trial with | 1 |
Latest dated events (14)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-01-22 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-08-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-12-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-10-19 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 14 events.
Biomarker capability evidence (6)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| KMT2A | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial exclusion criteria |
| GH1 | Trial sponsor | Named in trial exclusion criteria |
| ALB | Trial sponsor | Mentioned in trial text |
| GH1 | Trial sponsor | Mentioned in trial text |
Showing 5 of 6 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, approved assets, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.